Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China.
Br J Radiol. 2024 Dec 1;97(1164):1925-1930. doi: 10.1093/bjr/tqae166.
To evaluate the efficacy and safety of drug eluting bead transarterial chemoembolization (D-TACE) combined with apatinib/camrelizumab in patients with advanced hepatocellular carcinoma (HCC) and hepatic arterioportal shunts (APSs).
From January 2021 to December 2022, the consecutive medical records of patients with advanced HCC and APS receiving D-TACE combined with apatinib/camrelizumab were reviewed for eligibility. Overall survival (OS), progression-free survival (PFS), tumour response, and adverse events (AEs) were assessed.
A total of 23 patients were included in this study, with a median follow-up of 11 months (range, 2-26 months). Eight patients (34.8%) achieved partial response; 13 (56.5%), stable disease; and 2 (8.7%), progressive disease. The objective response and disease control rates were 34.8% and 91.3%, respectively. The OS and PFS rates were 11 and 7 months, respectively. Multivariate analysis indicated that the tumour number was an independent prognostic factor for PFS. AEs occurred in 19 patients after oral apatinib treatment and in 8 patients after camrelizumab treatment. No treatment-related death occurred during the study period.
D-TACE combined with apatinib/camrelizumab showed meaningful efficacy and controllable AEs in these patients, making it a promising treatment option.
(1) We investigated a new treatment strategy for patients with advanced HCC and hepatic APS and (2) D-TACE combined with apatinib/camrelizumab demonstrated meaningful efficacy and manageable AEs, making it a promising treatment option.
评估载药微球动脉化疗栓塞术（D-TACE）联合阿帕替尼/卡瑞利珠单抗治疗晚期肝细胞癌（HCC）合并肝动脉-门静脉分流（APS）患者的疗效和安全性。
回顾性分析 2021 年 1 月至 2022 年 12 月期间接受 D-TACE 联合阿帕替尼/卡瑞利珠单抗治疗的晚期 HCC 合并 APS 患者的病历资料，评估其总生存期（OS）、无进展生存期（PFS）、肿瘤反应和不良事件（AEs）。
本研究共纳入 23 例患者，中位随访时间为 11 个月（范围 2-26 个月）。8 例（34.8%）患者获得部分缓解，13 例（56.5%）患者病情稳定，2 例（8.7%）患者疾病进展。客观缓解率和疾病控制率分别为 34.8%和 91.3%。OS 和 PFS 率分别为 11 个月和 7 个月。多因素分析表明肿瘤数目是 PFS 的独立预后因素。19 例患者在口服阿帕替尼治疗后和 8 例患者在卡瑞利珠单抗治疗后出现 AEs。研究期间无治疗相关死亡。
D-TACE 联合阿帕替尼/卡瑞利珠单抗在这些患者中显示出有意义的疗效和可控制的 AEs，是一种有前途的治疗选择。
（1）我们研究了一种治疗晚期 HCC 合并 APS 患者的新治疗策略；（2）D-TACE 联合阿帕替尼/卡瑞利珠单抗显示出有意义的疗效和可管理的 AEs，是一种有前途的治疗选择。
